Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Roshini Claire Anthony, 6 days ago

Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.

No additional quality of life benefits of early palliative care in recently diagnosed malignant pleural mesothelioma

Pank Jit Sin
30 Oct 2017

The introduction of early specialist palliative care for patients recently diagnosed with malignant pleural mesothelioma (MPM) has no impact on the quality of life (QOL) scores, reveals a research presented by Professor Fraser Brims, of Curtin University Australia, at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held recently in Yokohama, Japan.

The RESPECT-MESO (Regular Early SPECialisT palliative care in malignant pleural MESOthelioma) trial is a multi-centre non-blinded randomized controlled trial to determine the impact of early specialist palliative care on quality of life on malignant mesothelioma. A total of 174 patients were randomized to receive either early palliative care plus standard care or just standard care alone. The group receiving early specialist care had a visit from specialists every 4 weeks throughout the course of the study.

Patients in the study had a median age of 72.6 years and 139 (79.9 percent) were male. At week 24, 30 participants had died and the overall median survival was 52 weeks.

Researchers utilized the EORTC QLQ-C30 questionnaire (for quality of life determination) and the General Health Questionnaire (GHQ-12) for anxiety or depression measurements. The primary outcome being monitored was the change in EORTC QLQ-C30’s QOL status at 12 weeks post randomization. At 12 weeks, there was no significant difference in quality of life between the specialist treated and standard treated groups.

Brims said it was evident from the trial results that there is no role for routine early referral to palliative care, regardless of symptoms, as there was no impact on quality of life or mood in recently diagnosed malignant pleural mesothelioma patients in the intervention group. As the study doesn’t provide clear results on what the optimal timing for referral is, that decision should continue to be based on clinicians’ judgement. Brims noted that future research into this question may be useful to review this practice to ensure optimal use of healthcare resources.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Roshini Claire Anthony, 6 days ago

Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.